glp 1 and liver disease 🔬 Big news for anyone managing fatty — this one's worth knowing about! A study just published this week in one of the world's top medical journals asked a question Frontiers | Future Perspectives on

Post-Market Surveillance Gap: Because AOD-9604 never received FDA approval for any indication, there is no post-market surveillance system capturing safety signals from widespread clinical use

Health experts including Dr Sobia Kauser have said that more studies urgently need to be conducted into how the long-term use of the tanning drug can impact a person

Bonus Tip: L-Carnitine Coffee Yes, its a thingand its trending

Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2